Update of the National Surgical Adjvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer

The selective estrogen-receptor modulator (SERM) tamoxifen became the first U.S. Food and Drug Administration (FDA)-approved agent for reducing breast cancer risk but did not gain wide acceptance for prevention, largely because it increased endometrial cancer and thromboembolic events. The FDA appro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Vogel, Victor G., Costantino, Joseph P., Wickerham, D. Lawrence, Cronin, Walter M., Cecchini, Reena S., Atkins, James N., Bevers, Therese B., Fehrenbacher, Louis, Pajon, Eduardo R., Wade, James L., Robidoux, Andre, Margolese, Richard G., James, Joan, Runowicz, Carolyn D., Ganz, Patricia A., Reis, Steven E., McCaskill-Stevens, Worta, Ford, Leslie G., Jordan, V. Craig, Wolmark, Norman
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2010
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2935331/
https://ncbi.nlm.nih.gov/pubmed/20404000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-10-0076
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge